DIEPENBEEK, Belgium, November 7, 2013 /PRNewswire/ --
Amakem Therapeutics, a clinical stage ophthalmology company, today announces that Dr. Jack Elands, CEO, will present at the Ophthalmology Innovation Summit (OIS) at the 2013 Annual Meeting of the American Academy of Ophthalmology.
Dr. Elands will present top-line clinical data on Amakem's lead drug candidate, the locally-acting Rho kinase (ROCK) inhibitor AMA0076 for the treatment of glaucoma. The presentation is scheduled to take place at the Sheraton New Orleans Hotel, New Orleans at 9.58am on Thursday November, 14.
Amakem is an ophthalmology company developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique Localized Drug Action platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
Amakem's lead candidate, AMA0076, is for glaucoma and entered clinical development late last year. The Company is also working to apply the Localized Drug Action approach to a range of other eye diseases.
Founded in 2010, Amakem has raised more than €21m in funding and is backed by leading life sciences investors including Forbion, Omnes Capital (previously Crédit Agricole), Vesalius BioCapital, LRM, PMV/Vinnof and Life Science Research Partners.
Amakem is based in Belgium and located in the life sciences incubator "BioVille" at the University of Hasselt. The Company has a long-standing collaboration with Professor Ingeborg Stalmans at the Ophthalmology Research Center of the University Leuven Hospital, where it sponsors a Chair in Ophthalmology Translational Research.